BARALDI, CARLO
 Distribuzione geografica
Continente #
EU - Europa 9.094
NA - Nord America 5.856
AS - Asia 2.623
SA - Sud America 429
Continente sconosciuto - Info sul continente non disponibili 148
AF - Africa 68
OC - Oceania 35
Totale 18.253
Nazione #
IT - Italia 6.607
US - Stati Uniti d'America 5.696
GB - Regno Unito 1.018
SG - Singapore 826
CN - Cina 569
BR - Brasile 319
VN - Vietnam 316
HK - Hong Kong 313
FR - Francia 273
SE - Svezia 194
DE - Germania 187
NL - Olanda 175
RU - Federazione Russa 127
BD - Bangladesh 100
IN - India 83
CH - Svizzera 74
KR - Corea 74
CA - Canada 72
UA - Ucraina 71
FI - Finlandia 68
TR - Turchia 64
ID - Indonesia 59
MX - Messico 54
ES - Italia 49
JP - Giappone 47
AR - Argentina 42
PL - Polonia 42
BG - Bulgaria 40
IE - Irlanda 36
AU - Australia 34
ZA - Sudafrica 21
AE - Emirati Arabi Uniti 19
IQ - Iraq 19
EC - Ecuador 18
EG - Egitto 17
IR - Iran 17
BE - Belgio 16
CO - Colombia 16
PK - Pakistan 16
TW - Taiwan 16
AT - Austria 15
PH - Filippine 15
MY - Malesia 11
NO - Norvegia 11
CR - Costa Rica 10
DK - Danimarca 10
CZ - Repubblica Ceca 9
HU - Ungheria 9
LT - Lituania 9
CL - Cile 8
GR - Grecia 8
NP - Nepal 8
AL - Albania 7
IL - Israele 7
JO - Giordania 7
PT - Portogallo 7
DZ - Algeria 6
PY - Paraguay 6
TN - Tunisia 6
UY - Uruguay 6
BY - Bielorussia 5
JM - Giamaica 5
KG - Kirghizistan 5
MA - Marocco 5
PE - Perù 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
VE - Venezuela 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
KE - Kenya 4
RS - Serbia 4
EE - Estonia 3
EU - Europa 3
GE - Georgia 3
GT - Guatemala 3
HR - Croazia 3
MD - Moldavia 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
AM - Armenia 2
CU - Cuba 2
GY - Guiana 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
MT - Malta 2
NI - Nicaragua 2
OM - Oman 2
SC - Seychelles 2
SI - Slovenia 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BZ - Belize 1
HN - Honduras 1
IS - Islanda 1
Totale 18.092
Città #
Southend 725
Ashburn 700
Milan 612
Singapore 515
Fairfield 507
Santa Clara 501
Rome 401
Chandler 315
Hong Kong 302
Woodbridge 252
San Jose 248
Houston 215
Seattle 215
Council Bluffs 181
Cambridge 178
Wilmington 164
Naples 151
Modena 144
Hefei 126
London 124
Beijing 121
Nyköping 119
Turin 118
Bologna 102
Ho Chi Minh City 102
New York 100
Los Angeles 97
Florence 93
Ann Arbor 86
Dearborn 82
The Dalles 79
Chicago 78
Hanoi 73
Seoul 59
Catania 58
Genoa 56
Palermo 55
Jacksonville 53
Bari 51
Helsinki 50
Lauterbourg 48
Jakarta 47
Verona 47
Parma 46
Moscow 42
San Diego 42
Dallas 40
Pescara 39
Shanghai 36
Cagliari 35
Princeton 32
São Paulo 32
Sofia 31
Salt Lake City 28
Zurich 28
Buffalo 27
Orem 27
Mexico City 26
Redwood City 25
Tokyo 25
Como 23
Munich 23
Warsaw 23
Amsterdam 21
Eugene 21
Atlanta 20
Brescia 20
Frankfurt am Main 20
L’Aquila 20
Dublin 19
Elk Grove Village 19
Fremont 19
Toronto 19
Chennai 18
Messina 18
Paris 18
Phoenix 18
Tampa 18
Padova 17
Ventimiglia 17
Bergamo 16
Boston 16
Columbus 16
Dalmine 16
Monza 16
Perugia 16
Brasília 15
Bremen 15
Da Nang 15
Haiphong 15
Manchester 15
Philadelphia 15
Reggio Emilia 15
Anápolis 14
Düsseldorf 14
Lucca 14
Montreal 14
Trento 14
Dong Ket 13
Istanbul 13
Totale 9.599
Nome #
Correlazione tra fumo di cannabis e pneumotorace spontaneo. 6.954
Allopregnanolone serum levels in female migraineurs 901
Seizures of illicit substances for personal use in two Italian provinces: analysis of trends by type and purity from 2008 to 2017 678
Development and validation of a liquid chromatography-tandem mass spectrometric assay for quantitative analyses of triptans in hair 521
Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study 432
Monitoring of adherence to headache treatments by means of hair analysis 406
Medication overuse and chronic migraine: a critical review according to clinical pharmacology 405
Hair testing in clinical setting: simultaneous determination of 50 psychoactive drugs and metabolites in headache patients by LC tandem MS 395
Comparison of pregnenolone sulfate, pregnanolone and estradiol levels between patients with menstrually-related migraine and controls: an exploratory study 367
Diagnostic accuracy of hair analysis for the detection of triptan overuse in migraineurs 354
A case-control study of visually evoked postural responses in childhood with primary headaches 318
Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache 312
Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study 297
Intrapatient variability of the hair levels of pain medications in chronic migraine patients - a pilot study 289
Secondary spontaneous pneumothorax and bullous lung disease in cannabis and tobacco smokers. A case-control study. 278
Anti-CGRP monoclonal antibodies improve cognitive function in patients affected by chronic migraine complicated with medication overuse-headache 276
Polypharmacy Among Headache Patients: A Cross-Sectional Study 271
Melanocortin receptor agonist NDP-α-MSH improves cognitive deficits and microgliosis but not amyloidosis in advanced stages of AD progression in 5XFAD and 3xTg mice 264
Hair testing as a marker of adherence to headache treatments 264
Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study 264
Serum changes of apolipoproteins in Medication Overuse Headache (MOH) 261
Glutamate receptor antagonists with the potential for migraine treatment 260
Proteomic serum profile in menstrual-related and post menopause migraine 257
Erenumab per il trattamento preventivo dell'emicrania cronica: efficacia e sicurezza fino a un anno, predittori di risposta ed effetti della sospensione. 256
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review 248
Proteomic serum profile of female migraineurs 242
Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age 233
Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study 212
Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data 194
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic 192
Visually Evoked Postural Responses (VEPRs) in Children with Vestibular Migraine 189
Occlusal splint therapy in patients with Ménière’s disease and temporomandibular joint disorder 183
Topical Cannabidiol in the Treatment of digital ulcers in patients with Scleroderma: comparative Analysis and Literature Review 176
OnabotulinumtoxinA: Still the Present for Chronic Migraine 165
Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real-world clinical evidence in a severely impaired patient population 159
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 159
Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study 152
Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study 140
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study 116
Evaluation of the risk of hypertension in patients treated with anti-CGRP monoclonal antibodies in a real-life study 110
Correction to: Monoclonal anti‑CGRP antibodies in post‑menopausal women: a real‑life study (Acta Neurologica Belgica, (2023), 123, 3, (1039-1047), 10.1007/s13760-023-02190-5) 103
Totale 18.253
Categoria #
all - tutte 50.812
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.812


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.180 0 0 114 138 48 79 64 116 127 117 220 157
2022/20232.537 166 191 187 224 189 230 188 229 305 139 252 237
2023/20242.547 212 213 227 207 265 193 238 221 160 185 225 201
2024/20253.140 178 151 145 267 432 385 259 206 333 195 279 310
2025/20264.174 332 170 260 540 751 247 506 196 362 369 228 213
2026/2027557 288 263 6 0 0 0 0 0 0 0 0 0
Totale 18.253